Surgical management of kidney cancer with associated vena cava tumor thrombus: A single-center multidisciplinary experience.

IF 0.8 Q4 UROLOGY & NEPHROLOGY
Vito Lorusso, Franco Palmisano, Valentina Bernasconi, Alessandra De Ponti, Chiara Vaccaro, Monica Contino, Antonio Maria Granata, Giacomo Piero Incarbone, Maria Chiara Sighinolfi, Bernardo Rocco, Andrea Gregori
{"title":"Surgical management of kidney cancer with associated vena cava tumor thrombus: A single-center multidisciplinary experience.","authors":"Vito Lorusso, Franco Palmisano, Valentina Bernasconi, Alessandra De Ponti, Chiara Vaccaro, Monica Contino, Antonio Maria Granata, Giacomo Piero Incarbone, Maria Chiara Sighinolfi, Bernardo Rocco, Andrea Gregori","doi":"10.1177/03915603251331358","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Kidney cancer (KC) with vena cava thrombus (VCT) is a rare but challenging disease. Surgery is associated with significant morbidity and mortality. The aim of our study is to report outcomes of patients with KC and VCT treated at our institution.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed data from 15 patients who underwent surgical treatment for KC with VCT at our institution between January 2004 and December 2022.</p><p><strong>Results: </strong>Median age of patients was 70 years (range: 66-77 years) and 13 (86%) were males. The level of thrombus was infrahepatic in 11 patients (73%), retrohepatic in 1 case (6%), and atrial in 3 patients (20%). Radical nephrectomy with vena cava thrombectomy was performed in all patients. Cardiopulmonary bypass was required in three patients (20%). The median operative time was 4.2 h (range: 4.0-4.6 h) and median estimated blood loss was 675 ml (range: 300-1500 ml). Postoperatively, eight patients (53%) experienced complications, and 5 (62%) were Clavien-Dindo >3. After a median follow-up of 15 months (range: 10-49 months), seven patients (46.5%) were alive without evidence of disease, one was alive with disease, among the remainder 7 (46.5%), 5/7 (72%) patients died of other causes, only 2/7 (28%) died because of cancer.</p><p><strong>Conclusions: </strong>Surgical resection of KC involving VCT represents a challenge for its high rate of complications. Multidisciplinary approach is often needed to achieve radicality safely. Oncological outcomes confirm the aggressiveness of the disease, with only roughly half (46.5%) of patients alive without disease at a median follow-up of 15 months.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251331358"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251331358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Kidney cancer (KC) with vena cava thrombus (VCT) is a rare but challenging disease. Surgery is associated with significant morbidity and mortality. The aim of our study is to report outcomes of patients with KC and VCT treated at our institution.

Materials and methods: We retrospectively analyzed data from 15 patients who underwent surgical treatment for KC with VCT at our institution between January 2004 and December 2022.

Results: Median age of patients was 70 years (range: 66-77 years) and 13 (86%) were males. The level of thrombus was infrahepatic in 11 patients (73%), retrohepatic in 1 case (6%), and atrial in 3 patients (20%). Radical nephrectomy with vena cava thrombectomy was performed in all patients. Cardiopulmonary bypass was required in three patients (20%). The median operative time was 4.2 h (range: 4.0-4.6 h) and median estimated blood loss was 675 ml (range: 300-1500 ml). Postoperatively, eight patients (53%) experienced complications, and 5 (62%) were Clavien-Dindo >3. After a median follow-up of 15 months (range: 10-49 months), seven patients (46.5%) were alive without evidence of disease, one was alive with disease, among the remainder 7 (46.5%), 5/7 (72%) patients died of other causes, only 2/7 (28%) died because of cancer.

Conclusions: Surgical resection of KC involving VCT represents a challenge for its high rate of complications. Multidisciplinary approach is often needed to achieve radicality safely. Oncological outcomes confirm the aggressiveness of the disease, with only roughly half (46.5%) of patients alive without disease at a median follow-up of 15 months.

肾癌伴腔静脉肿瘤血栓的外科治疗:单中心多学科经验。
肾癌(KC)合并腔静脉血栓(VCT)是一种罕见但具有挑战性的疾病。手术与显著的发病率和死亡率相关。我们研究的目的是报告在我们机构治疗的KC和VCT患者的结果。材料和方法:我们回顾性分析了2004年1月至2022年12月在我院接受VCT手术治疗的15例KC患者的数据。结果:患者年龄中位数为70岁(66-77岁),男性13例(86%)。血栓水平为肝下11例(73%),肝后1例(6%),心房3例(20%)。所有患者均行根治性肾切除术及腔静脉取栓术。3例患者(20%)需要体外循环。中位手术时间为4.2 h(范围:4.0-4.6 h),中位估计失血量为675 ml(范围:300-1500 ml)。术后出现并发症8例(53%),Clavien-Dindo bb3 5例(62%)。中位随访15个月(范围:10-49个月),7例(46.5%)无疾病生存,1例(46.5%)有疾病生存,其余7例(46.5%)中,5/7(72%)的患者死于其他原因,只有2/7(28%)的患者死于癌症。结论:手术切除累及VCT的KC是一个挑战,其并发症发生率高。通常需要多学科的方法来安全地实现根治性。肿瘤结果证实了该疾病的侵袭性,在中位随访15个月时,只有大约一半(46.5%)的患者无疾病存活。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Urologia Journal
Urologia Journal UROLOGY & NEPHROLOGY-
CiteScore
0.60
自引率
12.50%
发文量
66
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信